March 19, 2023
2 min learn
Supply/Disclosures
Printed by:
Simpson E. Dupilumab remedy in sufferers with hand and foot atopic dermatitis: Outcomes from a section 3, randomized, double-blind, placebo-controlled trial. Introduced at: American Academy of Dermatology Annual Assembly; March 17-21, 2023; New Orleans.
Disclosures:
Eichenfield experiences having monetary relationships with AbbVie, Almirall, Amryt Pharma, Arcutis Biotherapeutics, ASLAN Prescribed drugs, Bristol Myers Squibb, Cutera Inc., Dermavant Sciences, Inc., Eli Lilly, Elsevier Inc., Forte Biosciences, Galderma Laboratories L.P., Incyte Company, Krystal Biotech Inc., LEO Pharma, Lilly ICOS LLC, Nobelpharma, Ortho Dermatologics, Pfizer Inc., Sanofi/Regeneron, TopMD, TrialSpark Inc., UCB, Verrica Prescribed drugs Inc. and Wiley-Blackwell.
Key takeaways:
- A complete of 40.3% of sufferers handled with dupilumab achieved IGA 0 or 1 in contrast with 16.7% of placebo-treated sufferers.
- Dupilumab considerably decreased itch in 52.2% of sufferers.
NEW ORLEANS — Sufferers with hand and foot atopic dermatitis skilled important enchancment with dupilumab, which sustained an appropriate security profile, in response to section 3 research outcomes introduced right here.
“These outcomes are the primary to focus on how Dupixent can enhance indicators and signs of atopic hand and foot dermatitis, which could be very tough to deal with,” Eric Simpson, MD, MCR, Frances J. Storrs Medical Dermatology Professor at Oregon Well being & Science College, instructed Healio regarding his presentation on the American Academy of Dermatology Annual Assembly. “On this trial, considerably extra sufferers handled with Dupixent skilled clear or nearly clear pores and skin and diminished itch, and in addition had enhancements in broader impacts of the illness reminiscent of pores and skin ache, sleep and hand eczema-related high quality of life, in comparison with placebo.”
Simpson introduced information from the randomized, double-blind LIBERTY-AD-HAFT section 3 trial of dupilumab (Dupixent, Sanofi/Regeneron) in 133 sufferers aged 12 years and older with reasonable to extreme hand and foot atopic dermatitis.
Eric Simpson
Sufferers had been randomly assigned to obtain dupilumab monotherapy (n = 67) or placebo (n = 66) for 16 weeks. Adults had been administered 300 mg each 2 weeks, whereas adolescents had been administered 200 mg/300 mg on the similar frequency.
Outcomes confirmed that the research met the first endpoint and all secondary endpoints. Considerably extra dupilumab-treated sufferers achieved the first endpoint of IGA 0 or 1 in contrast with placebo-treated sufferers (40.3% vs. 16.7%; P = .003).
Of the dupilumab group, 52.2% achieved the important thing secondary endpoint of a 4 level or larger enchancment within the Hand and Foot Pruritus Numerical Score Scale in contrast with 13.6% within the placebo group (P < .0001).
The % change from baseline was considerably increased within the dupilumab group in contrast with the placebo group in modified Whole Lesion Signal Rating (LS imply, 69.4; customary error [SE], 5.8 vs. LS imply, 31; SE, 5.9; P < .0001) and Hand Eczema Severity Index (LS imply, 74.8; SE, 6.3 vs. LS imply, 39.9; SE, 6.2; P < .0001).
The research reported an appropriate security profile with the commonest remedy emergent antagonistic occasions in dupilumab and placebo teams together with nasophyngitis (16% vs. 11%, respectively) and atopic dermatitis (5% vs. 18%).
“Given the sturdy security and efficacy profile Dupixent has already proven from infancy to maturity in folks with reasonable to extreme atopic dermatitis, we had been hopeful to see optimistic ends in these with atopic dermatitis targeting the fingers and toes,” Simpson stated. “We’re happy to see such sturdy ends in sufferers that have intense itch and painful pores and skin lesions on such vital areas of the physique.”
